| Name | Title | Contact Details |
|---|
Moonlighting Solutions is a physician-owned and operated company that provides hospitals with short and long-term physician coverage, specializing in night and weekend call coverage. They also offer permanent placement opportunities for their moonlight...
Helen Keller Hospital is a not-for-proft, community hospital in Sheffield, AL. An acute care facility, Helen Keller Hospital is licensed to operate 185 beds. History Colbert County and the City of Sheffield opened a Hospital, March 22, 1921. At the time, this was called Colbert County Hospital. It is now known as Helen Keller Memorial Hospital, part of the Colbert County Healthcare Authority. Other healthcare entities under the umbrella the Colbert County Healthcare Authority include Red Bay Hospital, North Alabama Sleep Disorders Center and Northwest Practice Management. On May 21, 1979, the name of the hospital was changed to Helen Keller Hospital in honor of that great lady and world-renowned humanitarian. The continued growth of the Northwest Alabama Healthcare Authority is a result of the dedication of the Board of Trustees, the citizens of Colbert County and the hospital employees, who deliver excellent patient care. Helen Keller Hospital is fully accredited by the Joint Commission on Accreditation of Hospitals assuring the finest in medical care by the process of review inspection and updating. The Authority is governed by a nine-member Board of Trustees from Colbert County appointed by the County Commission serving in staggered six-year terms. While the Board of Trustees is ultimately responsible for the operation of the Authority, the details are delegated to the Authority President.
Baker Dental Corp is a Hawthorn Woods, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Us Respiratory is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.